ZA202101113B - Therapeutic or prophylactic agent of htlv-1-associated myelopathy (ham), and method for treating ham - Google Patents

Therapeutic or prophylactic agent of htlv-1-associated myelopathy (ham), and method for treating ham

Info

Publication number
ZA202101113B
ZA202101113B ZA2021/01113A ZA202101113A ZA202101113B ZA 202101113 B ZA202101113 B ZA 202101113B ZA 2021/01113 A ZA2021/01113 A ZA 2021/01113A ZA 202101113 A ZA202101113 A ZA 202101113A ZA 202101113 B ZA202101113 B ZA 202101113B
Authority
ZA
South Africa
Prior art keywords
ham
htlv
therapeutic
prophylactic agent
treating
Prior art date
Application number
ZA2021/01113A
Other languages
English (en)
Inventor
Kaoru Uchimaru
Makoto Yamagishi
Izumi Ishizaki
Yoshihisa Yamano
Original Assignee
Univ Tokyo
Univ School St Marianna Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo, Univ School St Marianna Medicine filed Critical Univ Tokyo
Publication of ZA202101113B publication Critical patent/ZA202101113B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2021/01113A 2018-07-19 2021-02-18 Therapeutic or prophylactic agent of htlv-1-associated myelopathy (ham), and method for treating ham ZA202101113B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018135925 2018-07-19
PCT/JP2019/028431 WO2020017629A1 (ja) 2018-07-19 2019-07-19 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法

Publications (1)

Publication Number Publication Date
ZA202101113B true ZA202101113B (en) 2022-07-27

Family

ID=69163691

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/01113A ZA202101113B (en) 2018-07-19 2021-02-18 Therapeutic or prophylactic agent of htlv-1-associated myelopathy (ham), and method for treating ham

Country Status (16)

Country Link
US (1) US20210269535A1 (cg-RX-API-DMAC7.html)
EP (2) EP4656657A3 (cg-RX-API-DMAC7.html)
JP (4) JP7150286B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210034055A (cg-RX-API-DMAC7.html)
CN (4) CN116850291A (cg-RX-API-DMAC7.html)
AU (1) AU2019306721B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000949A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112511A1 (cg-RX-API-DMAC7.html)
IL (1) IL280257A (cg-RX-API-DMAC7.html)
MX (1) MX2021000732A (cg-RX-API-DMAC7.html)
PE (2) PE20260298A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550134A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100561QA (cg-RX-API-DMAC7.html)
TW (2) TWI825131B (cg-RX-API-DMAC7.html)
WO (1) WO2020017629A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101113B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2025070749A1 (cg-RX-API-DMAC7.html) * 2023-09-29 2025-04-03

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
WO2005087268A1 (ja) * 2004-03-11 2005-09-22 Bioclues, Inc 軸索再生促進剤
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN102131571B (zh) 2008-09-02 2014-03-05 东丽电池隔膜株式会社 微孔性高分子膜、该膜的制备方法及该膜作为电池隔膜的应用
JP5552630B2 (ja) 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法
KR102284780B1 (ko) 2009-12-09 2021-08-02 미쓰비시 타나베 파마 코퍼레이션 T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법
CA2824515C (en) * 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
JP5963233B2 (ja) * 2011-12-07 2016-08-03 学校法人 聖マリアンナ医科大学 Htlv−1関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法
JP6310845B2 (ja) * 2012-07-06 2018-04-11 学校法人 聖マリアンナ医科大学 Htlv−1関連脊髄症患者の治療方法および治療剤
WO2016038084A1 (en) 2014-09-10 2016-03-17 AbbVie Deutschland GmbH & Co. KG Rgma fragment based diagnostic assay
CA2983898A1 (en) * 2015-04-28 2016-11-03 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TW202523689A (zh) * 2016-06-01 2025-06-16 美商艾伯維有限公司 治療脊髓損傷及疼痛之方法
US10772887B2 (en) * 2016-08-03 2020-09-15 Kagoshima University Anti-HTLV-1 drug and therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)

Also Published As

Publication number Publication date
TW202408577A (zh) 2024-03-01
JP2024095754A (ja) 2024-07-10
KR20210034055A (ko) 2021-03-29
CN112566664B (zh) 2023-08-25
CN112566664A (zh) 2021-03-26
CN116942831A (zh) 2023-10-27
PE20211376A1 (es) 2021-07-27
JPWO2020017629A1 (ja) 2021-08-02
PE20260298A1 (es) 2026-02-10
CN116850291A (zh) 2023-10-10
JP2022180487A (ja) 2022-12-06
JP2025134820A (ja) 2025-09-17
CA3112511A1 (en) 2020-01-23
EP3824907B1 (en) 2025-09-17
SG11202100561QA (en) 2021-02-25
IL280257A (en) 2021-03-25
WO2020017629A1 (ja) 2020-01-23
EP3824907A1 (en) 2021-05-26
TWI825131B (zh) 2023-12-11
EP3824907A4 (en) 2022-05-04
EP4656657A3 (en) 2026-02-25
JP7475011B2 (ja) 2024-04-26
AU2019306721A1 (en) 2021-03-11
PH12021550134A1 (en) 2021-09-27
EP4656657A2 (en) 2025-12-03
MX2021000732A (es) 2021-04-28
CN116785439A (zh) 2023-09-22
JP7703174B2 (ja) 2025-07-07
BR112021000949A2 (pt) 2021-04-27
AU2019306721B2 (en) 2024-09-05
JP7150286B2 (ja) 2022-10-11
TW202019482A (zh) 2020-06-01
US20210269535A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
SG11202009864UA (en) Gas treatment system and ship including same
EP3871756A4 (en) Exhaust gas treatment system and method
ES3065724T3 (en) Method for control and after-treatment of workpieces, control system and treatment installation
SG11201706561SA (en) Apparatus for treatment of waste gas and method for treating the same
GB201904299D0 (en) An exhaust gas treatment system and the use thereof for the treatment of an exhaust gas
GB202205698D0 (en) Medical treatment devie and method of operation thereof
IL275156A (en) A system and method for cognitive development or device-based therapy
SG11202007546YA (en) Water treatment apparatus, water treatment method, and method of starting water treatment apparatus
IL282611A (en) Method and system for producing non-thermal plasma
IL287138A (en) System and method for water treatment
PL3511212T3 (pl) Instalacja przetwarzająca i sposób przetwarzania przedmiotów obrabianych
PT3612475T (pt) Instalação de tratamento
HUE064901T2 (hu) Kezelõrendszer munkadarabok kezelésére
IL280257A (en) Therapeutic or prophylactic agent for HTLV-1-associated myelopathy (HAM) and method for treating HAM
EP3723695A4 (en) METHOD AND DEVICE FOR THERAPEUTIC GAS TREATMENT
ZA202100468B (en) Apparatus, method and computer program for emergency call
EP3972609C0 (en) OXATHIAZINE DIOXIDE FOR THE TREATMENT, PREVENTION, INHIBITION OR REDUCTION OF CYTOKINE RELEASE
HUE058014T2 (hu) Kezelõberendezés munkadarabok kezeléséhez
IL289090A (en) System and method for gas treatment
GB201703039D0 (en) Exhaust gas treatment system and method
GB201804051D0 (en) Emergency lighting apparatus, associated method and computer program instructions
GB2584704B (en) Gas treatment process and gas treatment apparatus
GB2581494B (en) Apparatus, system and method of authentication
SG11202112211VA (en) Gas treatment method and gas treatment device
GB202103646D0 (en) Waste treatment, apparatus and method